 "Cipla shares gain 5% after USFDA okays capsules; m-cap rises by Rs 3,021 cr")
Shares of drug firm Cipla on Friday gained over 5 per cent after the company said it has received the final approval from the US health regulator for Dimethyl Fumarate capsules.
The stock jumped 5.10 per cent to close at Rs 770.20 on the BSE. During the day, it rose by 5.97 per cent to Rs 776.60.
On the NSE, it gained 4.99 per cent to settle at Rs 770.10.
The company's market valuation also rose by Rs 3,021.11 crore to Rs 62,104.11 crore.
The newly approved product is a generic therapeutic equivalent version of Biogen IDEC Inc's Tecfidera.
Cipla has received final approval for its abbreviated new drug application (ANDA) for Dimethyl Fumarate DR (delayed release) capsules in the strengths of 120mg, 240mg and 120mg and 240mg from the United States Food and Drug Administration (USFDA), the company said in a regulatory filing.
The capsule is indicated for the treatment of relapsing forms of multiple sclerosis.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%